BNP Paribas Asset Management
PHAT icon

BNP Paribas Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

BNP Paribas Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.72K Buy
896
+7
+0.8% +$80 ﹤0.01% 2235
2026
Q1 		$9.88K Buy
889
+285
+47% +$3.6K ﹤0.01% 2216
2025
Q4 		$10K Buy
+604
New +$8.63K ﹤0.01% 2147

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BNP Paribas Asset Management's PHAT Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Phathom Pharmaceuticals (PHAT) stake by 0.79% in Q2 2026, buying an estimated $80 and bringing the position to 896 shares worth $9.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

BNP Paribas Asset Management first reported a position in PHAT in Q4 2025 and has held it in 3 quarters since. The position peaked at $10K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • BNP Paribas Asset Management held 896 shares of Phathom Pharmaceuticals worth $9.72K as of Q2 2026.
  • BNP Paribas Asset Management bought 7 Phathom Pharmaceuticals shares in Q2 2026, an estimated $80.
  • Phathom Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2235 holding.
  • BNP Paribas Asset Management first reported a position in Phathom Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • BNP Paribas Asset Management's Phathom Pharmaceuticals position peaked at $10K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.